Cancer research moves fast. We make it understandable.
In the randomized, open-label, phase 3 KEYNOTE-689 trial, adding pembrolizumab before and after surgery to standard treatment significantly extended event-free survival in patients with resectable, locally advanced, PD-L1-positive head and…
Primary source cited
Last reviewed
In the randomized, phase 3 BRUIN-CLL-321 trial, pirtobrutinib -- the first and only non-covalent (reversible) BTK inhibitor -- significantly extended progression-free survival compared with standard chemoimmunotherapy options in patients with…
Primary source cited
Last reviewed
In cohort 1 of the single-arm, phase 2b HERIZON-BTC-01 trial, zanidatamab -- a bispecific antibody that binds two separate sites on the HER2 protein -- produced a confirmed objective response…
Primary source cited
Last reviewed
In the randomized, phase 3 ECOG-ACRIN E1910 trial, adding blinatumomab to consolidation chemotherapy significantly extended overall survival compared with chemotherapy alone in adults with MRD-negative B-cell precursor ALL — the…
Primary source cited
Last reviewed
In the LIBRETTO-121 trial's primary efficacy population of 25 pediatric and young adult patients with RET-altered solid tumors (including RET-altered thyroid cancer) that had not responded to available therapies, selpercatinib…
Primary source cited
Last reviewed
In a small, phase 1, first-in-human trial, a personalized cancer vaccine built from each patient's own tumor mutations was given after surgery to patients with high-risk kidney cancer. All 9…
Primary source cited
Last reviewed
FAST-02 is a single-arm feasibility trial testing proton FLASH radiotherapy -- an experimental technique that delivers a full course of radiation in under 1 second, more than 100 times faster…
Primary source cited
Last reviewed
In two separate, randomized, double-blind, phase 3 trials (SPOTLIGHT and GLOW), adding zolbetuximab to first-line chemotherapy significantly extended both progression-free survival and overall survival, compared with chemotherapy alone, in patients…
Primary source cited
Last reviewed
In the prospective, single-arm, phase 2 ROBOCOLO trial, robotic-assisted surgery for resectable right-sided colon cancer met its primary safety endpoint (postoperative complication rate within 30 days), supporting robotic surgery as…
Primary source cited
Last reviewed
In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with…
Primary source cited
Last reviewed